Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) has been given an average rating of “Buy” by the twenty-eight ratings firms that are presently covering the stock. Eleven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $117.63.

A number of brokerages have issued reports on VRTX. Piper Jaffray Cos. restated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Saturday, June 18th. Leerink Swann set a $112.00 target price on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, September 17th. Jefferies Group restated a “buy” rating and set a $103.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, June 17th. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 21st. Finally, Vetr lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating and set a $94.50 price objective for the company. in a research report on Tuesday, June 14th.

Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 92.12 on Tuesday. Vertex Pharmaceuticals has a 52-week low of $75.90 and a 52-week high of $134.71. The stock’s market cap is $22.83 billion. The company’s 50 day moving average is $97.07 and its 200-day moving average is $89.55.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.03. The company earned $431.61 million during the quarter, compared to analysts’ expectations of $428.08 million. Vertex Pharmaceuticals had a negative net margin of 17.77% and a negative return on equity of 12.34%. The firm’s quarterly revenue was up 159.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.54) earnings per share. On average, equities analysts anticipate that Vertex Pharmaceuticals will post $1.00 earnings per share for the current year.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 5,130 shares of the stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $84.82, for a total transaction of $435,126.60. Following the sale, the director now directly owns 273,355 shares of the company’s stock, valued at $23,185,971.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Joshua S. Boger sold 5,140 shares of the stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $88.99, for a total transaction of $457,408.60. Following the sale, the director now directly owns 273,365 shares in the company, valued at $24,326,751.35. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the company. Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $859,000. Kentucky Retirement Systems acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $1,809,000. Northwestern Mutual Investment Management Company LLC boosted its stake in shares of Vertex Pharmaceuticals by 0.3% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 9,435 shares of the pharmaceutical company’s stock worth $812,000 after buying an additional 28 shares during the period. Mason Street Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $2,866,000. Finally, Public Employees Retirement System of Ohio boosted its stake in shares of Vertex Pharmaceuticals by 1.3% in the second quarter. Public Employees Retirement System of Ohio now owns 167,562 shares of the pharmaceutical company’s stock worth $14,414,000 after buying an additional 2,160 shares during the period. 96.19% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.